临床前CDMO研发筛选相关化合物

CDMO是Contract Development and Manufacturing Organization的缩写，即合同定制研发生产组织。它是一种为制药企业及生物技术公司提供医药（特别是创新药）工艺研发及制备、工艺优化、放大生产、注册和验证批生产以及商业化生产等定制服务的机构. 在传统代工基础上增加了研发和工艺优化能力，是高技术壁垒的工艺研发能力与规模生产能力的深度结合. 1, 工艺开发与优化：创新性合成路线设计、工艺参数优化. 2, 中试放大：实验室工艺向规模化生产的转化 3, 注册批生产：支持客户新药申报的验证批生产. 4, 商业化生产：药品上市后的大规模生产供应. 全球医药CDMO行业保持较高景气度。根据弗若斯特沙利文预测：2026年全球CDMO市场规模：预计达1,189亿美元 2033年全球CDMO市场规模：预计达3,385亿美元. CDMO作为医药产业链专业化分工的产物，已经从单纯的CMO代工模式升级为"研发+生产"一体化的高附加值服务。当前，在多肽、ADC、CGT等新型药物赛道的驱动下，全球及中国CDMO市场保持高速增长。中国CDMO企业凭借完整的供应链体系、工程师红利和一体化服务能力，全球市占率有望持续提升，行业正从"成本优势"竞争迈向"体系优势"竞争的新阶段。
如有产品调研服务, 请致函联系我们

客户展示

临床前CDMO研发化合物筛选

CAS: 39831-55-5

Amikacin disulfate

中文名称:硫酸阿米卡星
CAS号:39831-55-5
分子式: C22H43N5O13.2H2SO4 分子量: 781.76
产品形式: Sulfate
研发状态: Recruiting
研发用途: Tuberculosis Multidrug-Resistant
研究机构: Rwanda Biomedical Centre; Institute of Tropical Medicine; World Health Organization
研发日期: March 1 2023
研发阶段: Phase 2
Amikacin sulfate (BB-K8) binds to 16S rRNA (bacterial 30S ribosome), causing misreading of mRNA and supressing proteins synthesis.

CAS: 39809-25-1

Penciclovir

中文名称:喷昔洛韦
CAS号:39809-25-1
分子式: C10H15N5O3 分子量: 253.26
产品形式: free base
研发状态: Completed
研发用途: Herpes Labialis
研究机构: Novartis Pharmaceuticals; Novartis
研发日期: March 25 2009
研发阶段: Phase 2 : Phase 3
Penciclovir (BRL-39123, VSA 671,NSC-759624) is a purine acyclic nucleoside analogue with potent antiviral activity.

CAS: 394730-60-0

Boceprevir

中文名称:波普瑞韦
CAS号:394730-60-0
分子式: C27H45N5O5 分子量: 519.68
产品形式: free base
研发状态: Completed
研发用途: Liver Transplantation
研究机构: Indiana University; Merck Sharp & Dohme LLC
研发日期: Jun-13
研发阶段: Early Phase 1
Boceprevir (EBP 520, SCH 503034) is an oral, direct acting hepatitis C virus (HCV) protease inhibitor with Ki value of 14 nM for NS3. It is used in combination with other antiviral agents in the treatment of chronic hepatitis C, genotype 1.

CAS: 39133-31-8

Trimebutine

中文名称:曲美布汀
CAS号:39133-31-8
分子式: C22H29NO5 分子量: 387.47
产品形式: free base
研发状态: Completed
研发用途: Pain; Cancer; Colonic Diseases
研究机构: gicare Pharma Inc.; JSS Medical Research Inc.; Algorithme Pharma Inc
研发日期: Jul-13
研发阶段: Phase 2
Trimebutine (Mebutin) is an agonist of peripheral mu, kappa and delta opiate receptors, used as spasmolytic agent for treatment of both acute and chronic abdominal pain.

CAS: 391210-10-9

Mirdametinib (PD0325901)

中文名称: N-[(2R)-2,3-二羟基丙氧基]-3,4-二氟-2-[(2-氟-4-碘苯)氨基]苯甲酰胺
CAS号:391210-10-9
分子式: C16H14F3IN2O4 分子量: 482.19
产品形式: free base
研发状态: Completed
研发用途: Solid Tumor; Colorectal Cancer
研究机构: University of Oxford; Queen''s University Belfast; Oxford University Hospitals NHS Trust; Velindre NHS Trust; University Hospital Antwerp; Hospital Vall d''Hebron; Saint Antoine University Hospital; European Georges Pompidou Hospital; Pfizer; University of Turin Italy; Belfast Health and Social Care Trust; Beaumont Hospital; European Commission; Array BioPharma; University of Paris 5 - Rene Descartes
研发日期: Nov-14
研发阶段: Phase 1
Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.

CAS: 388082-77-7

Lapatinib (GW-572016) Ditosylate

中文名称: 二对甲苯磺酸拉帕替尼
CAS号:388082-77-7
分子式: C29H26ClFN4O4S.2C7H8O3S 分子量: 925.46
产品形式: Ditosylat
研发状态: Withdrawn
研发用途: Breast Cancer
研究机构: University of New Mexico
研发日期: July 31 2023
研发阶段: Phase 1 : Phase 2
Lapatinib (GW-572016) Ditosylate is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively.